ABSTRACT. The iacrerse in the number of human immunodeficiency virus-1 (HIV-1)infected children is a direct consequence of the heterosexual spread of the disease to women and the growing number of HIV-positive i.v. drug users. It is not known bow the majority of infants born to HIV-1-infected women escape HIV-1 infection, and, for those infected, the timing of HIV-1 transmission bas yet to be determined. In addition, the role of maternal antibodies in the prevention of HIV-1 transmission to the fetus is unclear. We have previously demonstmted a correlation between vertical transmission and the absence of high-affinity/avidity antibodies to a peptide, KIU-HIGPGRAFYT, which corresponds to a region of the primary neutralizing domain of the gplm V3 loop of HIVm (MN-PND). The present study examines the correlation between the presence of these bigb PfRnity antibodies in women completing a prelplnncy or undergohg an elective abortion and the dctection of HIV-1 infection in their aborted fetuses. In several instance% transmission occurred despite high-affinity antibodies to the MN-PND. We have, therefore, evaluated the reactivity of sera to different MN-PND variants. In ow infant born to a mother with l@hffimIty/avidity antibodies to KRI- Various studies in the United States and in Europe show a maternofetal transmission rate of between 9 and 70% (1-6). The reasons for the variation over this wide range of rates of transmission are unknown. Recent studies have suggested that perinatal transmission may play a more prominent role than has been appreciated previously (7-10). Conversely, using the PCR, we (1 1, 12) and others (13-16) have determined the presence of the HIV-1 genome in a variety of fetal tissues obtained from elective pregnancy terminations of HIV-1-seropositive women. Our studies have shown a maternofetal transmission rate of approximately 30% by the end of the 2nd trimester (1 1). In our initial study of fetal tissues obtained from 2nd trimester abortuses of HIV-1-infected women, HIV-1 genomic sequences were detected in 30% (1 1, 12). This percentage was identical to the transmission rate m r d e d in babies born to HIV-1-infected women in the Bronx (1). In the present study, we have attempted to determine the fetal HIV-1 status in amniotic fluids obtained during pregnancy. In addition, we have investigated the correlation of transmission with the presence of high-affinity antibodies to the MN-PND.
Various studies in the United States and in Europe show a maternofetal transmission rate of between 9 and 70% (1-6). The reasons for the variation over this wide range of rates of transmission are unknown. Recent studies have suggested that perinatal transmission may play a more prominent role than has been appreciated previously (7-10). Conversely, using the PCR, we (1 1, 12) and others (13-16) have determined the presence of the HIV-1 genome in a variety of fetal tissues obtained from elective pregnancy terminations of HIV-1-seropositive women. Our studies have shown a maternofetal transmission rate of approximately 30% by the end of the 2nd trimester (1 1). In our initial study of fetal tissues obtained from 2nd trimester abortuses of HIV-1-infected women, HIV-1 genomic sequences were detected in 30% (1 1, 12). This percentage was identical to the transmission rate m r d e d in babies born to HIV-1-infected women in the Bronx (1) . In the present study, we have attempted to determine the fetal HIV-1 status in amniotic fluids obtained during pregnancy. In addition, we have investigated the correlation of transmission with the presence of high-affinity antibodies to the MN-PND. STUDY DESIGN Patients. Blood and amniotic fluid were obtained at delivery from 18 women with known fetal outcome. The status of infection of infants was determined by clinical, serologic (ELISA, W e s t e r n blot), and virologic methods (viral culture and PCR) as has previously been reported by us (1 3). Babies born to HIV-1 -infected women were followed for more than 15 mo. This study is part of an ongoing research protocol that has been approved by the Albert Einstein College of Medicine Committee on Clinical Investigation and the Health and Hospitals Corporation of the City of New York. Informed consent was obtained from the
participants.
Methods. The HIV-1 ELISA and Western blot were perfomed with commercially available ELISA kits (DuPont, Boston, MA) and W e s t e r n blot strips (DuPontjBiotech). Immune complexes in amniotic fluid were precipitated with polyethylene glycol and disrupted at 37'C for 60 min. HIV-1 p24 antigen was then detembed using a commercial Antigen Capture ELISA kit (DuPont). IgG, IgM, and IgA anti-HIV-1 present in the disrupted complexes were determined using commercial Westem blot strips (DuPont/Biotech) developed with alkaline-phosphataseconjugated antibodies directed against human IgA, IgM, and 1 6 .
The antigen-limiting ELISA was performed as previously reported (17). In a m&cation of the previous method, some ELSA plates were coated with four different peptides: 1) KRI- Fesults (20) (21) (22) (23) (24) (25) . We have shown in pPeliminary studies that high- -1-m~w o m c n i n t h e s a m c~a r e a . I t i s~c u l t t o a c c u r a t d 
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